What question did this study set out to answer?

To explore recent developments in the treatment of IgA nephropathy and their implications.

February 13, 2026

Targeting the Pathogenesis of IgA Nephropathy — A New Treatment Approach?

Key Points

To explore recent developments in the treatment of IgA nephropathy and their implications.
Review of current guidelines and recent advancements in the management of IgA nephropathy.
Analysis of treatment approaches relative to the pathogenesis of the disease.
IgA nephropathy is the most common primary glomerulonephritis.
Recent treatments show promise in reducing proteinuria and improving glomerular filtration rate.
Immunosuppressive treatment remains controversial due to its toxic effects.

Abstract

IgA nephropathy, first described in 1968 by Berger and Hinglais, 1 is the most common form of primary glomerulonephritis. For decades, IgA nephropathy was considered to have a relatively good prognosis, and so most patients received conservative treatment, with immunosuppressive treatment reserved for those with severe proteinuria or progressive decline in the estimated glomerular filtration rate (eGFR). Global guidelines from as late as 2021 indicated that the benefits of immunosuppression, which has known toxic effects, were uncertain. 2 However, within the past 5 years, an astonishing change in how clinicians think about and treat IgA nephropathy has occurred, with five new agents . . .

اسأل الذكاء الاصطناعي

Bookmark